Health disparities in ethnic and racial minority populations with pain and opioid use disorder
DOI:
https://doi.org/10.5055/jom.2023.0796Keywords:
addiction, pain, opioid, policy, underserved populationsAbstract
Healthcare providers are not prepared to address health disparities among ethnic and racial minority populations with either persistent and chronic pain or substance use disorder (SUD). Recognizing biases from policies to provide pain management and treatment for SUD in our healthcare systems, from our individual state laws and federal guidelines, is necessary. Biases are embedded in the screening and treatment of patients with chronic pain through the use of screening tools, opioid treatment agreements, and prescription drug monitoring programs. Additionally, the punitive treatment of people of ethnic and racial minority populations who experience persistent and chronic pain, opioid use disorders, or other SUDs needs to be redirected to facilitate solutions rooted in equity.
References
Nelson ZJ, Stellpflug SJ, Engebretsen KM: What can a urine drug screening immunoassay really tell us? J Pharm Practice. 2016; 29(5): 516-526. DOI: https://doi.org/10.1177/0897190015579611
St. Marie B: Healthcare experiences when pain and substance use disorder coexist. Pain Med. 2014; 15(12): 2075-2086. DOI: 10.1111/pme.12493. DOI: https://doi.org/10.1111/pme.12493
Takeshita J, Wang S, Loren AW, et al.: Association of racial/ ethnic and gender concordance between patients and physicians with patient experience ratings. JAMA Netw Open. 2020; 3(11): e2024583. DOI: 10.1001/jamanetworkopen.2020.24583. DOI: https://doi.org/10.1001/jamanetworkopen.2020.24583
United States Census Bureau: Profile of general population and housing characteristics. Available at https://data.census.gov/table?q=Profile+of+general+population+and+housing+characteristics.&g=010XX00US&tid=DECENNIALDP2020.DP1. Accessed September 27, 2023.
Association of American Medical Colleges (AAMC): 2022 physician specialty data. AAMC. 2023. Available at https://www.aamc.org/search?keys=2022%20physician%20specialty%20data. Accessed September 27, 2023.
Association of American Medical Colleges (AAMC): Active physicians who identified as White. 2021. Available at https://www.aamc.org/data-reports/workforce/data/active-physicianswhite-2021. Accessed September 27, 2023.
Association of American Medical Colleges (AAMC): Active physicians who identified as Asian. 2021. Available at https://www.aamc.org/data-reports/workforce/data/active-physiciansasian-2021. Accessed September 27, 2023.
Association of American Medical Colleges (AAMC): Active physicians who identified as Hispanic (alone or with any race). 2021. Available at https://www.aamc.org/data-reports/workforce/data/active-physicians-hispanic-alone-or-any-race-2021. Accessed September 27, 2023.
Association of American Medical Colleges (AAMC): Active physicians who identified as Black or African American. 2021. Available at https://www.aamc.org/data-reports/workforce/data/active-physicians-black-african-american-2021. Accessed September 27, 2023.
Association of American Medical Colleges (AAMC): Active physicians who identified as American Indian or Alaska native. 2021. Available at https://www.aamc.org/data-reports/workforce/data/active-physicians-american-indian-alaskanative-2021. Accessed September 27, 2023.
Association of American Medical Colleges (AAMC): Active physicians who identified as native Hawaiian or other pacific islander. 2021. Available at https://www.aamc.org/data-reports/workforce/data/active-physicians-native-hawaiian-otherpacific-islander-2021. Accessed September 27, 2023.
Association of American Medical Colleges (AAMC): Number of people per active physician by specialty. 2021. Available at https://www.aamc.org/data-reports/workforce/data/numberpeople-active-physician-specialty-2021. Accessed September 27, 2023.
Gopal DP, Chetty U, O’Donnell P, et al.: Implicit bias in healthcare: Clinical practice, research and decision making. Future Healthc J. 2021; 8: 40-48. DOI: 10.7861/fhj.2020-0233. DOI: https://doi.org/10.7861/fhj.2020-0233
Hoffman KM, Trawalter S, Axt JR, et al.: Racial bias in pain assessment and treatment recommendations, and false beliefs about biological differences between Blacks and Whites. Proc Natl Acad Sci USA. 2016; 113(16): 4296-4301. DOI: 10.1073/pnas.1516047113. DOI: https://doi.org/10.1073/pnas.1516047113
Booker SQ, Baker TA, Epps F, et al.: Interrupting biases in the experience and management of pain. Am J Nurs. 2022; 122(9): 48-54. DOI: 10.1097/01.NAJ.0000874120.95373.40. DOI: https://doi.org/10.1097/01.NAJ.0000874120.95373.40
Ly DP: Racial and ethnic disparities in the evaluation and management of pain in the outpatient setting, 2006–2015. Pain Med. 2019; 20(2): 223-232. DOI: 10.1093/pm/pny074. DOI: https://doi.org/10.1093/pm/pny074
Engel-Rebitzer E, Dolan AR, Aronowitz SV, et al.: Patient preference and risk assessment in opioid prescribing disparities: A secondary analysis of a randomized clinical trial. JAMA Netw Open. 2021; 4(7): e2118801. DOI: 10.1001/jamanetworkopen.2021.18801. DOI: https://doi.org/10.1001/jamanetworkopen.2021.18801
Badreldin N, Grobman WA, Yee LM: Racial disparities in postpartum pain management. Ob Gyn. 2019; 134(6): 1147-1153. DOI: 10.1097/AOG.0000000000003561. DOI: https://doi.org/10.1097/AOG.0000000000003561
Morden NE, Chyn D, Wood A, et al.: Racial inequality in prescription opioid receipt-role of individual health systems. N Engl J Med. 2021; 385: 342-351. DOI: 10.1056/NEJMsa2034159. DOI: https://doi.org/10.1056/NEJMsa2034159
Romanelli RJ, Shen Z, Szwerinski N, et al.: Racial and ethnic disparities in opioid prescribing for long bone fractures at discharge from the emergency department: A cross-sectional analysis of 22 centers from a health care delivery system in Northern California. Annals Emerg Med. 2019; 74(5): 622-631. DOI: https://doi.org/10.1016/j.annemergmed.2019.05.018
Maly A, Vallerand AH: Neighborhood, socioeconomic, and racial influence on chronic pain. Pain Manag Nurs. 2018; 19(1): 14-22. DOI: 10.1016/j.pmn.2017.11.004. DOI: https://doi.org/10.1016/j.pmn.2017.11.004
Robinson-Lane SG, Vallerand AH: Pain treatment practices of community-dwelling Black older adults. Pain Manag Nurs. 2018; 19(1): 46-53. DOI: 10.1016/j.pmn.2017.10.009. DOI: https://doi.org/10.1016/j.pmn.2017.10.009
Booker SQ: African Americans’ perceptions of pain and pain management: A systematic review. J Transcult Nurs. 2016; 27(1): 73-80. DOI: 10.1177/1043659614526250. DOI: https://doi.org/10.1177/1043659614526250
Osborn M, Smith JA: The personal experience of chronic benign lower back pain: An interpretative phenomenological analysis. Br J Health Psych. 1998; 3: 65-83. DOI: https://doi.org/10.1111/j.2044-8287.1998.tb00556.x
Healthy People 2030: United States Department of health and human services, office of disease prevention and health promotion: Social determinants of health 2023. Available at https://health.gov/healthypeople/priority-areas/social-determinants-health. Accessed September 27, 2023.
Brown TT, Partanen J, Chuong L, et al.: Discrimination hurts: The effect of discrimination on the development of chronic pain. Soc Sci Med. 2018; 204: 1-8. DOI: 10.1016/j.socscimed.2018.03.015. DOI: https://doi.org/10.1016/j.socscimed.2018.03.015
Perry M, Baumbauer K, Young EE, et al.: The influence of race, ethnicity and genetic variants on postoperative pain intensity: An integrative literature review. Pain Manag Nurs. 2019; 20(3): 198-206. DOI: 10.1016/j.pmn.2018.11.002. DOI: https://doi.org/10.1016/j.pmn.2018.11.002
Booker SQ, Herr KA: The state of “cultural validity” of self-report pain assessment tools in diverse older adults. Pain Med. 2015; 16(2): 232-239. DOI: 10.1111/pme.12496. DOI: https://doi.org/10.1111/pme.12496
Orhan C, Van Looveren E, Cagnie B, et al.: Are pain beliefs, cognitions, and behaviors influenced by race, ethnicity, and culture in patients with chronic musculoskeletal pain: A systematic review. Pain Phys. 2018; 21(6): 541-558. DOI: https://doi.org/10.36076/ppj.2018.6.541
Matteliano D, St. Marie B, Oliver J, et al.: Adherence monitoring with chronic opioid therapy for persistent pain: A biopsychosocial-spiritual approach to mitigate risk. Pain Manag Nurs. 2014; 15(1): 391-405. DOI: https://doi.org/10.1016/j.pmn.2012.08.008
National Institute on Drug Abuse: Drug overdose death rates. Available at https://nida.nih.gov/research-topics/trendsstatistics/overdose-death-rates. Accessed September 27, 2023.
Centers for Disease Control and Prevention: Drug overdose death rise, disparities widen: Differences grew by race, ethnicity, and other factors. Available at https://www.cdc.gov/vitalsigns/overdose-death-disparities/index.html#:~:text=Overdose%20death%20rates%20in%20older,older%20White%20men%20in%202020.&text=Overdose%20death%20rates%20for%20younger,younger%20White%20women%20in%202020. Accessed September 27, 2023.
Chang JE, Franz B, Cronin CE, et al.: Racial/ethnic disparities in the availability of hospital-based opioid use disorder treatment. J Subst Abuse Treat. 2022; 138: 108719. DOI: 10.1016/j.jsat.2022.108719. DOI: https://doi.org/10.1016/j.jsat.2022.108719
Morales ME, Yong RJ: Racial and ethnic disparities in the treatment of chronic pain. Pain Med. 2021; 22: 75-90. DOI: 10.1093/pm/pnaa427. DOI: https://doi.org/10.1093/pm/pnaa427
Wakeman SE, Lambert E, Kung S, et al.: Trends in buprenorphine treatment disparities during the COVID pandemic in Massachusetts. Subst Abuse. 2022; 43(1): 1317-1321. DOI: 10.1080/08897077.2022.2095077. DOI: https://doi.org/10.1080/08897077.2022.2095077
Hansen HB, Siegel CE, Galanter M: Variation in use of buprenorphine and methadone treatment by racial, ethnic and income characteristics of residential social areas in New York City. J Behav Health Serv Res. 2019; 40(3): DOI: 10.1007/s11414-013-9341-3. DOI: https://doi.org/10.1007/s11414-013-9341-3
James K, Jordan A: The opioid crisis in Black communities. J Law Med Ethics. 2018; 46: 404-421. DOI: https://doi.org/10.1177/1073110518782949
Substance Abuse and Mental Health Administration: The opioid crisis and the Black/African American Population: An urgent issue. Publication No. PEP20-05-02-001. Office of Behavioral Health Equity. Substance Abuse and Mental Health Services Administration, 2020.
Donnelly EA, Wagner J, Stenger M, et al.: Opioids, race, and drug enforcement: Exploring local relationships between neighborhood context and Black-White opioid-related possession arrests. Crim Just Policy Rev. 2020; 32(3): DOI: 10.1177/0887403420911415. DOI: https://doi.org/10.1177/0887403420911415
Netherland J, Hansen HB: The war on drugs that wasn’t: Wasted whiteness, “dirty doctors,” and race in media coverage of prescription opioid misuse. Cult Med Psychiatry. 2016; 40(4): 664-686. DOI: 10.1007/s11013-016-9496-5. DOI: https://doi.org/10.1007/s11013-016-9496-5
Pierson E, Simoiu C, Overgoor J, et al.: A large-scale analysis of racial disparities in police stops across the United States. Nat Hum Behav. 2020; 4: 736-745. DOI: 10.1038/s41562-020-0858-1. DOI: https://doi.org/10.1038/s41562-020-0858-1
Rich JD, McKenzie M, Larney S, et al.: Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: A randomized, open-label trial. Lancet. 2015; 386(9991): 350-359. DOI: 10.1016/S0140-6736(14)62338-2. DOI: https://doi.org/10.1016/S0140-6736(14)62338-2
Gaither JR, Gordon K, Crystal S, et al.: Racial disparities in discontinuation of long-term opioid therapy following illicit drug use among Black and White patients. Drug Alcohol Dep. 2018; 192: 371-376. DOI: 10.1016/j.drugalcdep.2018.05.033. DOI: https://doi.org/10.1016/j.drugalcdep.2018.05.033
Buonara M, Perez HR, Heo M, et al.: Race and gender are associated with opioid dose reduction among patients on chronic opioid therapy. Pain Med. 2019; 20(8): 1519-1527. DOI: 10.1093/pm/pny137. DOI: https://doi.org/10.1093/pm/pny137
Winchester ML, Shahiri P, Boevers-Solverson E, et al.: Racial and ethnic differences in urine drug screening on labor and delivery. Matern Child Health J. 2022; 26: 124-130. DOI: 10.1007/s10995-021-03258-5. DOI: https://doi.org/10.1007/s10995-021-03258-5
St Marie B, Coleman L, Vignato J, et al.: Use and misuse of opioid pain medications by pregnant and nonpregnant women. Pain Manag Nurs. 2020; 21: 90-93. DOI: 10.1016/j.pmn.2019.05.002. DOI: https://doi.org/10.1016/j.pmn.2019.05.002
Beck AS, Svirsky L, Howard D: First do no harm’: Physician, discretion, racial disparities, and opioid treatment agreements. J Med Ethics. 2022; 48: 753-758. DOI: https://doi.org/10.1136/medethics-2020-107030
Dickson-Gomez J, Christenson E, Weeks M, et al.: Effects of implementation and enforcement differences in prescription drug monitoring programs in 3 states: Connecticut, Kentucky, and Wisconsin. Subst Abuse. 2021; 15: 117822182199234. DOI: 10.1177/1178221821992349. DOI: https://doi.org/10.1177/1178221821992349
Olivia JD: Dosing discrimination: Regulating PDMP risk scores. California Law Review. 2022. Available at https://www.californialawreview.org/print/dosing-discrimination-regulating-pdmp-risk-scores. Accessed September 27, 2023. DOI: https://doi.org/10.2139/ssrn.3768774
Andrews CM, Pollack HA, Abraham AJ, et al.: Medicaid coverage in substance use disorder treatment after the affordable care act. J Subst Abuse Treat. 2019; 102: 1-7. DOI: 10.1016/j.jsat.2019.04.001. DOI: https://doi.org/10.1016/j.jsat.2019.04.002
Yue D, Rasmussen PW, Ponce NA: Racial/ethnic differential effects of Medicaid expansion on health care access. Health Serv Res. 2018; 53(5): 3640-3656. DOI: 10.1111/1475-6773.12834. DOI: https://doi.org/10.1111/1475-6773.12834
Margerison CE, MacCallum CL, Chen J, et al.: Impacts of Medicaid expansion on health among women of reproductive age. Am J Preventive Med. 2020; 58(1): 1-11. DOI: https://doi.org/10.1016/j.amepre.2019.08.019
Heyward J, Jones CM, Compton WM, et al.: Coverage of nonpharmacologic treatments for low back pain among US public and private insurers. JAMA Netw Open. 2018; 1(6): e183044. DOI: 10.1001/jamanetworkopen.2018.3044. DOI: https://doi.org/10.1001/jamanetworkopen.2018.3044
Medicaid.gov: About section 1115 demonstrations. Available at https://www.medicaid.gov/medicaid/section-1115-demonstrations/about-section-1115-demonstrations/index.html. Accessed September 27, 2023.
Arkansas Department of Human Services: Demonstration waiver projects: Public notice and input processes for 1115(A) demonstration waiver applications/renewals/amendments/public hearings. Available at https://humanservices.arkansas.gov/divisions-shared-services/medical-services/demonstrationwaiver-projects/. Accessed September 27, 2023.
Centers for Medicare & Medicaid Services: HHS approves California’s Medicaid and children’s health insurance plan (CHIP) demonstration authority to support care for justice-involved people. 2023. Available at https://www.hhs.gov/about/news/2023/01/26/hhs-approves-californias-medicaid-andchildrens-health-insurance-plan.html. Accessed September 27, 2023.
Office of National Drug Control Policy: 2022. Available at https://www.whitehouse.gov/ondcp/. Accessed September 27, 2023.
Barnes MC, Kelly TJ, Piemonte CM: Demanding better: A case for increased funding and involvement of state medical boards in response to America’s drug abuse crisis. J Med Regul. 2020; 106(3): 6-21. DOI: 10.30770/2572-1852-106.3.6. DOI: https://doi.org/10.30770/2572-1852-106.3.6
Barnes MC: A more sensible surge: Ending DOJ’s indiscriminate raids of healthcare providers. Legis Policy Brief. 2019; 8(1). Article 3. Available at https://digitalcommons.wcl.american.edu/cgi/viewcontent.cgi?article=1071&context=lpb. Accessed September 27, 2023.
Dowell D, Haegerich TM, Chou R: CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016; 315(15): 1624-1645. DOI: https://doi.org/10.1001/jama.2016.1464
Bicket MC, Waljee J, Fernandez AC: Unintended consequences from the 2016 US centers for disease control and prevention guideline for prescribing opioids—Accelerating change in postoperative prescribing. JAMA Netw Open. 2021; 4(6): e2111997. DOI: 10.1001/jamanetworkopen.2021.11997. DOI: https://doi.org/10.1001/jamanetworkopen.2021.11997
Dowell D, Ragan KR, Jones CM, et al.: CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. MMWR Recomm Rep. 2022; 71(3): 1-95. Available at https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm?s_cid=rr7103a1_w. Accessed September 27, 2023. DOI: https://doi.org/10.15585/mmwr.rr7103a1
Substance Abuse and Mental Health Services Administration: Harm reduction. Available at https://www.samhsa.gov/find-help/harm-reduction. Accessed September 27, 2023.
Network for Public Health Law (NPHL): Naloxone. Available at https://www.networkforphl.org/resources/legal-interventionsto-reduce-overdose-mortality-naloxone-access-and-goodsamaritan-laws/. Accessed September 27, 2023.
National Institute on Drug Abuse: Advancing addiction science. Naloxone saves lives. Available at https://nida.nih.gov/publications/naloxone-opioid-overdose-life-saving-science. Accessed September 27, 2023.
US Food & Drug Administration: FDA approves first over-the-counter naloxone nasal spray. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-overcounter-naloxone-nasal-spray. Accessed September 27, 2023.
Harris E: FDA approves nalmefene, a longer-lasting opioid reversal nasal spray. JAMA Netw. 2023; 329: 2012. Available at https://jamanetwork.com/journals/jama/articleabstract/2805739. Accessed September 27, 2023. DOI: https://doi.org/10.1001/jama.2023.9608
Krieter P, Gyaw S, Crystal R, et al.: Fighting fire with fire: Development of intranasal nalmefene to treat synthetic opioid overdose. J Pharmacol Exp Ther. 2019; 371(2): 409-415. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863453/. Accessed September 27, 2023. DOI: https://doi.org/10.1124/jpet.118.256115
US Food & Drug Administration: FDA approves prescription nasal spray to reverse opioid overdose. Available at https://www.fda.gov/news-events/press-announcements/fda-approvesprescription-nasal-spray-reverse-opioid-overdose. Accessed September 27, 2023.
Kariisa M, Davis NL, Kumar S, et al.: Vital signs: Drug overdose deaths, by selected sociodemographic and social determinants of health characteristics—25 states and the District of Columbia, 2019-2020. MMWR Morb Mortal Wkly Rep. 2022; 71: 940-947. Available at https://www.cdc.gov/mmwr/volumes/71/wr/mm7129e2.htm?s_cid=mm7129e2_w. Accessed September 27, 2023.
Tabak LA: Overdose Prevention Centers. Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse. Available at https://nida.nih.gov/sites/default/files/NIH-RTC-Overdose-Prevention-Centers.pdf. Accessed September 27, 2023.
Beletsky L, Davis CS, Anderson E, et al.: The law (and politics) of safe injection facilities in the United States. Am J Public Health. 2008; 98(2): 231-237. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376869/. Accessed September 27, 2023. DOI: https://doi.org/10.2105/AJPH.2006.103747
Alfonseca K, Kekatos M: Why opioid overdose prevention programs work as NYC leads nation with 1st center. ABC News. Available at https://abcnews.go.com/health/opioid-overdose-pre vention-programs-work-nyc-leads-nation/story?id=82835105. Accessed September 27, 2023.
Feldman N: In Philadelphia, judges rule against opening ‘supervised’ site to inject opioids. NPR. Available at https://www.npr.org/sections/health-shots/2021/01/14/956428659/in-philadelphia-judges-rule-against-opening-a-medical-site-to-safelyinject-hero. Accessed September 27, 2023.
Diep F: How supervised injection sites can save cities money: Researchers have released two of the first cost-benefit analyses of supervised injection facilities in US cities. Pacific Standard. Available at https://psmag.com/economics/howsupervised-injection-sites-can-help-users-and-cities. Accessed September 27, 2023.
Kennedy MC, Karamouzian M, Kerr T: Public health and public order outcomes associated with supervised drug consumption facilities: A systematic review. Curr HIV/AIDS Rep. 2017; 14: 161-183. DOI: https://doi.org/10.1007/s11904-017-0363-y
Samuels EA, Bailer DA, Yolken A: Overdose prevention centers: A essential strategy to address the overdose crisis. JAMA Netw Open. 2022; 5(7): e22221532794326. Available at https://jamanetwork.com/searchresults?q=overdose%20prevention%20centers%3A%20a%20essential%20strategy%20to%20address%20the%20overdose%20crisis&allSites=1&SearchSourceType=1&exPrm_qqq={DEFAULT_BOOST_FUNCTION}%22overdose%20prevention%20centers%3A%20a%20essential%20strategy%20to%20address%20the%20overdose%20crisis%22&exPrm_hl.q=overdose%20prevention%20centers%3A%20a%20essential%20strategy%20to%20address%20the%20overdose%20crisis. Accessed September 27, 2023.
Centers for Disease Control and Prevention: Fentanyl test strips: A harm reduction strategy. Available at https://www.cdc.gov/stopoverdose/fentanyl/fentanyl-test-strips.html. Accessed September 27, 2023.
Ireland N: Fentanyl test strips could lead to false sense of security, health Canada warns. Available at https://www.cbc.ca/news/health/fentanyl-test-strips-false-negatives-health-canada-1.4447392. Accessed September 27, 2023.
Facher L: Fentanyl test strips could help save lives. In many states, they’re still illegal. Available at https://www.statnews.com/2022/09/08/fentanyl-test-strips-could-help-save-lives-inmany-states-theyre-still-illegal/. Accessed September 27, 2023.
Warm Handoff: Community paramedicine. 2023. Available at https://warmhandoff.org/. Accessed September 27, 2023.
Samples H, Nowels MA, Williams AR, et al.: Buprenorphine after nonfatal opioid overdose: Reduced mortality risk in Medicare disability beneficiaries. Am J Prev Med. 2023; 65: 19-29. Available at https://www.ajpmonline.org/article/S0749-3797(23)00052-1/fulltext. Accessed September 27, 2023. DOI: https://doi.org/10.1016/j.amepre.2023.01.037
Ober AJ, Watkinsa KE, McCullougha CM, et al.: Patient predictors of substance use disorder treatment initiation in primary care. J Subst Abuse Treat. 2018; 90: 64-72. DOI: https://doi.org/10.1016/j.jsat.2018.04.004
Substance Abuse and Mental Health Administration: Recommendations for curricular elements in substance use disorders training. 2023. Available at https://www.samhsa.gov/medications-substance-use-disorders/provider-support-services/recommendations-curricular-elements-substance-use-disorders-training?utm_source=SAMHSA. Accessed September 27, 2023.
Substance Abuse and Mental Health Administration: Removal of DATA waiver (X-Waiver) requirement. 2023. Available at https://www.samhsa.gov/medications-substance-use-disorders/waiver-elimination-mat-act. Accessed September 27, 2023.
California Emergency Medical Services Authority: Introduction to community paramedicine. Available at https://emsa.ca.gov/community_paramedicine/. Accessed September 27, 2023.
Community Impact North Carolina: Community paramedicine to help people who use substances: Overview and recommendations. Available at https://centerforuspolicy.org/wpcontent/uploads/2021/01/Community-Paramedicine-Overview.pdf. Accessed September 27, 2023.
Rahim F, Jain B, Patel T, et al.: Community paramedicine: An innovative model for value-based care delivery. J Public Health Manag Pract. 2022; (2): E65-E68. DOI: 10.1097/PHH.0000000000001683. DOI: https://doi.org/10.1097/PHH.0000000000001683
Published
How to Cite
Issue
Section
License
Copyright 2005-2024, Weston Medical Publishing, LLC
All Rights Reserved
